Requip Related Published Studies
Well-designed clinical trials related to Requip (Ropinirole)
Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. [2007.12]
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.12]
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. [2007.04.03]
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. [2007.03.15]
The weight of evidence for ropinirole in restless legs syndrome. [2006.10]
Ropinirole is effective in the long-term management of restless legs syndrome: A randomized controlled trial. [2006.10]
Ropinirole treatment for restless legs syndrome. [2006.09]
Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. [2006.01]
Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. [2005.03]
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. [2004.12]
Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. [2004.08.01]
Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. [2004.07]
Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. [2004.04.27]
Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. [2004.01]
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. [2003.07]
Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. [2003.01]
Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. [2003]
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. [2003]
A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. [2002.12]
Ropinirole for the treatment of tremor in early Parkinson's disease. [2002.05]
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. [2002.04]
Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. [2002.02.12]
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. [2000.05.18]
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. [1999.07.22]
The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. [1999.02]
Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. [1999.02]
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. [1998.10]
Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. [1998.09]
The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. [1998.05]
Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. [1998.04]
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. [1998.03]
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. [1998.01]
Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. [1998.01]
Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. [1997.08]
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. [1996.06]
Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. [1991.10]
Well-designed clinical trials possibly related to Requip (Ropinirole)
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. [2004.10]
A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. [2004.07]
[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol] [2000.12]
A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist. [1989.10]
Other research related to Requip (Ropinirole)
Ropinirole treatment for restless legs syndrome. [2008.03]
Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl. [2008.02.19]
Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. [2008.01.26]
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. [2007.12.15]
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.12.15]
Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease. [2007.12]
Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. [2007.11.15]
A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. [2007.11]
Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. [2007.10.15]
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. [2007.10.12]
Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males. [2007.10]
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.09.25]
Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. [2007.07.30]
Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. [2007.07.06]
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy] [2007.04]
Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations. [2007.04]
Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. [2007.03.15]
The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers. [2007.01.17]
Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. [2006.11.17]
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. [2006.11]
The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers. [2006.10.18]
Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme. [2006.10]
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. [2006.09.06]
[Ropinirole in the treatment of Parkinson's disease: an update] [2006.05.01]
Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients. [2006.05]
Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat. [2006.03]
[Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study] [2005.10]
Ropinirole, a non-ergoline dopamine agonist. [2005.09]
Ropinirole in treatment-resistant depression: a 16-week pilot study. [2005.05]
Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. [2005.05]
Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. [2005.01.30]
Ropinirole in the treatment of restless legs syndrome. [2005.01]
Ropinirole: current status of the studies. [2004.09]
Ropinirole therapy for Parkinson's disease. [2004.07]
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. [2004.06]
Ropinirole in Gilles de la Tourette syndrome. [2004.05.11]
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. [2004.01]
Ropinirole: for the treatment of restless legs syndrome. [2004]
In vivo iontophoretic administration of ropinirole hydrochloride. [2003.12]
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. [2003.11]
High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. [2003.05]
Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. [2003]
Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. [2003]
Ropinirole for antidepressant-induced sexual dysfunction. [2002.11]
Dosing with ropinirole in a clinical setting. [2002.10]
Ropinirole in restless leg syndrome. [2002.09]
Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation. [2001.12]
Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. [2001.11]
Warfarin and ropinirole interaction. [2001.10]
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). [2001.07]
High-dose therapy with ropinirole in patients with Parkinson's disease. [2001]
Clinical pharmacokinetics of ropinirole. [2000.10]
Ropinirole: a review of its use in the management of Parkinson's disease. [2000.07]
Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. [2000.06]
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys. [2000.03]
Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. [2000]
Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. [2000]
Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. [1999.12]
[The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data] [1999.11.01]
Ropinirole and pramipexole, the new agonists. [1999.08]
|
